NEOGENOMICS INC (NEO) SEC Filings

NEOGENOMICS INC (NEO) reported that officer Warren Stone, President & Chief Operating Officer, exercised 28,106 Restricted Stock Units into an equal number of shares of common stock on August 21, 2026. On the same date, 11,060 shares of common stock were delivered or withheld for payment of exercise price or tax liability. The filing also lists Mr. Stone’s remaining equity incentives, including multiple tranches of stock options, restricted stock units, and performance stock units that vest over future dates and, once vested, common shares that are not subject to expiration.

First Light Asset Management, LLC and Mathew P. Arens report their beneficial ownership of NeoGenomics, Inc. common stock. First Light Asset Management may be deemed to beneficially own 10,260,186 shares, representing 7.99% of the common stock. These shares are held in separately managed accounts and private funds for which the Manager serves as investment adviser.

Mathew P. Arens may be deemed to beneficially own 10,759,586 shares, or 8.37% of the common stock, including 235,000 shares held directly with sole control and 264,400 shares in a joint account with shared control. Voting and dispositive powers are primarily shared through the Manager. The reporting persons state that these disclosures are made solely for purposes of Section 13(d) of the Exchange Act and are not an admission of beneficial ownership for other purposes.

NeoGenomics, Inc. reported that Alicia Olivo, Executive Vice President, General Counsel & Business Development, will transition from her role and cease to serve as General Counsel effective September 21, 2026. She will remain an employee through October 2, 2026 for transitional purposes.

The company states that, in connection with her departure, Ms. Olivo will be eligible to receive separation payments and benefits in line with Section 5(b) of her employment agreement, which had been filed previously as part of NeoGenomics’ Form 10-K for the year ended December 31, 2025.

NeoGenomics Inc. chief accounting officer Greg D. Aunan reported selling 20,000 shares of Common Stock on 2026-08-04 at $16.07 per share, leaving 5,153 shares held directly. He continues to hold multiple equity awards, including restricted stock units for 10,745 underlying shares and stock options for 28,662, 26,978, 31,163 and 36,825 underlying shares with exercise prices between $9.83 and $14.62.

NEO has a shareholder filing to sell 20,000 shares of common stock, with an aggregate market value of $321,480.00, through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with a proposed sale date of August 4, 2026.

The filing also lists multiple tranches of common stock underlying restricted stock vesting under a registered plan for services rendered, with vesting dates from May 1, 2024 through May 2, 2026 and share amounts ranging from 1,606 to 4,448.

NEO filed a notice of proposed sale of common stock under Rule 144 through Morgan Stanley Smith Barney LLC’s Executive Financial Services program, to be effected on or after July 30, 2026 on Nasdaq. The shares to be sold stem from equity compensation granted under registered plans.

The filing lists restricted stock that vested on December 7, 2023 (for services rendered), May 11, 2024, and December 7, 2024, as well as common stock issuable upon an option exercise under a registered plan on July 30, 2026 for cash consideration.

BlackRock, Inc. filed an amended beneficial ownership report for NeoGenomics, Inc. common stock. BlackRock reports beneficial ownership of 20,358,331 shares, representing 15.6% of the outstanding common stock. Of these, 19,688,877 shares carry sole voting power and all 20,358,331 shares carry sole dispositive power.

The filing states that these holdings reflect securities beneficially owned, or deemed to be beneficially owned, by certain BlackRock business units, excluding other disaggregated units. It also notes that iShares Core S&P Small-Cap ETF has an interest in NeoGenomics common stock that is more than five percent of the total outstanding common stock.

NeoGenomics, Inc. is reported to have 10,113,261 shares of its common stock beneficially owned by First Trust Portfolios L.P., First Trust Advisors L.P. and The Charger Corporation, representing 7.77% of the class. First Trust Advisors L.P. and The Charger Corporation report shared voting and shared dispositive power over these shares, while First Trust Portfolios L.P. reports no voting or dispositive power.

The position is largely held through unit investment trusts sponsored by First Trust Portfolios L.P. and other investment vehicles advised by First Trust Advisors L.P. All three reporting entities jointly file under Rule 13d-1(k)(1) and expressly disclaim beneficial ownership of the reported shares.

NeoGenomics, Inc. reported net revenue of $201,656 (dollars in thousands) for the quarter ended June 30, 2026, up from $181,330 a year earlier, with gross profit increasing to $91,878. Operating expenses declined, partly due to the absence of prior-year impairment charges, and loss from operations narrowed to $9,771 (all in thousands).

After interest income and an $11,181 gain on extinguishment of debt, NeoGenomics generated quarterly net income of $2,238 versus a prior-year net loss of $45,092 (dollars in thousands); for the first six months, it recorded a net loss of $14,868 on revenue of $388,328. Cash and cash equivalents were $145,539, and total stockholders’ equity $785,732 (dollars in thousands) as of June 30, 2026.

During the quarter, the company issued $316.3 million of 0.75% Convertible Senior Notes due 2032, using proceeds to repurchase a portion of its 2028 notes for $262.9 million in cash, enter $28.7 million of equity-classified capped call transactions, and repurchase 2,383,222 shares for $25.0 million. A subsequent civil settlement with the U.S. Department of Justice requires payment of $10.0 million and reduced a previously recorded reserve by about $1.2 million, producing a benefit in general and administrative expense.